Mode
Text Size
Log in / Sign up
Phase 2 N=128 Randomized Quadruple-blind Treatment

Clinical Study to Test a New Drug to Treat Major Depression

Depressive Disorder, Major

Enrolled (actual)
128
Serious AEs
1.6%
Results posted
Nov 2017
Primary outcome: Primary: Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score. — -6.5; -5.6 Scores on scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
GW856553 (Drug); Placebo (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Jul 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score.
-6.5; -5.6
SECONDARY
Number of Participants With Adverse Events
28; 26; 1; 1
SECONDARY
Number of Participants With Suicidality as Assessed by the Columbia Suicidality Severity Rating Scale Score
55; 57; 54; 55; 49; 54
SECONDARY
Number of Participants With Abnormal Haematology and Clinical Chemistry Values
1; 0; 1; 0
SECONDARY
Number of Participants With Abnormal Vital Signs (Blood Pressure, Heart Rate)
1; 0; 1; 0
SECONDARY
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
0; 0
SECONDARY
Changes From Randomization (Week 0)in IL-6 and TNF-alpha Associated With GW856553 Versus Placebo at Week 1 and Week 6 in the Morning Plasma Levels
-1.06; -0.27; -1.86; -1.57; -0.67; -0.96
SECONDARY
Change From Randomisation Bech Total Score: Bech Score
-1.2; -1.6; -2.5; -2.2; -3.9; -3.4
SECONDARY
Mean HAMD-17 Total Score
21.7; 21.2; 18.9; 19.7; 16.5; 17.8
SECONDARY
Mean Inventory of Depressive Symptomatology Clinician (IDS-C) Total Score
39.7; 39.2; 35.2; 35.9; 30.9; 32.4
SECONDARY
Mean IDS-SR Total Score
34.7; 38.1; 29.2; 32.8; 24.7; 27.5
SECONDARY
Mean Quick Inventory of Depressive Symptomatology Self Report-16 Item (QIDS-SR16) Total Score Derived From the IDS-SR (Only at Weeks 0, 2, 4 and 6)
18.0; 17.8; 13.0; 14.1; 10.6; 11.8
SECONDARY
Percentage of IDS-C Responders (Participants With a Reduction in Total Score of ≥50% From Randomization at Week 6/Study Exit).
50; 41
SECONDARY
Percentage of IDS-C Remitters (Participants Whose Total Score Was ≤ 15 at Week 6/Study Exit).
38; 18
SECONDARY
Percentage of IDS-SR Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).
49; 47
SECONDARY
Percentage of IDS-SR Remitters (Participants Whose Total Score Was ≤ 15 at Week 6/Study Exit).
37; 19
SECONDARY
Percentage of QIDS-SR16 Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).
55; 45
SECONDARY
Percentage of QIDS-SR16 Remitters (Subjects Whose Total Score Was ≤ 5 at Week 6/Study Exit).
31; 13
SECONDARY
Percentage of Bech Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).
62; 49
SECONDARY
Percentage of Bech Remitters (Participants Whose Total Score Was ≤ 4 at Week 6/Study Exit).
38; 20
SECONDARY
Percentage of Participants With a Clinicians Global Impression of Improvement (CGI-I) Score of 1 ("Very Much Improved") or 2 ("Much Improved") at Weeks 1, 2, 3, 4, 5 and 6.
10; 8; 28; 14; 41; 39
SECONDARY
Assessment of Clinical Global Impression-Severity of Illness (CGI-S) up to 6 Weeks
0; 1.59; 0; 1.69; 1.96; 3.51

Summary

In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with MDD. Subjects will receive oral doses of GW856553 or placebo for six weeks. Safety, tolerability, pharmacokinetics and pharmacodynamics, defined as biomarkers in blood and clinical symptoms, will be assessed. The primary endpoint is the change from baseline associated with GW856553 versus placebo at Week 6 in the Bech (6-item HAMD-17) score. Interim analyses of the primary endpoint will be performed throughout the study to potentially adapt the study design by changing the randomization ratio and/ or reducing the total number of subjects to be randomized into the study. Exploratory analyses will be performed by associating changes in cytokine levels and selected clinical symptoms; PK/PD modelling will also be used to identify the most sensitive clinical and biological markers.

Eligibility Criteria

Key Inclusion Criteria

  • Adult subjects with primary diagnosis of moderate to severe MDD without psychotic features, for at least 4 weeks and one previous MDD episode
  • Males or Females who agree to use protocol specified contraception if of child bearing potential
  • BMI 18.5-35.0 kg/m2
  • Normal liver function tests

Key Exclusion Criteria

  • History of liver disease or positive hepatitis B surface antigen or hepatitis C antibody in the last 3 months
  • Elevated liver function tests on >2 ocassions in the last 7 months
  • Significant medical illness, autoimmune disease or infectious disease
  • Pregnant or nursing females
  • Excessive and regular alcohol consumption
  • History of substance abuse or dependence in past 6 months or positive urine drug screen
  • Significant suicidal or homicidal risk
  • Currently receiving chronic biological or pharmacologic anti-inflammatory therapy or is not euthyroid
  • Psychoactive drugs within 1 week or 5 half lives of randomization visit
  • Treatment resistant subjects
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00976560). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search